tradingkey.logo

scPharmaceuticals Inc

SCPH
View Detailed Chart
5.670USD
0.000
Close 12/22, 16:00ETQuotes delayed by 15 min
302.16MMarket Cap
LossP/E TTM

scPharmaceuticals Inc

5.670
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

0.00%

6 Months

+47.66%

Year to Date

+60.17%

1 Year

+67.26%

View Detailed Chart

Key Insights

scPharmaceuticals Inc's fundamentals are relatively healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.

scPharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
99 / 174
Overall Ranking
263 / 4702
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
12.088
Target Price
+113.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

scPharmaceuticals Inc Highlights

StrengthsRisks
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.33M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 131.14.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.14M shares, decreasing 13.57% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.84M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.31.

scPharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

scPharmaceuticals Inc Info

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Ticker SymbolSCPH
CompanyscPharmaceuticals Inc
CEOMr. John H. Tucker
Websitehttps://www.scpharmaceuticals.com/

FAQs

What is the current price of scPharmaceuticals Inc (SCPH)?

The current price of scPharmaceuticals Inc (SCPH) is 5.670.

What is the symbol of scPharmaceuticals Inc?

The ticker symbol of scPharmaceuticals Inc is SCPH.

What is the 52-week high of scPharmaceuticals Inc?

The 52-week high of scPharmaceuticals Inc is 6.280.

What is the 52-week low of scPharmaceuticals Inc?

The 52-week low of scPharmaceuticals Inc is 1.940.

What is the market capitalization of scPharmaceuticals Inc?

The market capitalization of scPharmaceuticals Inc is 302.16M.

What is the net income of scPharmaceuticals Inc?

The net income of scPharmaceuticals Inc is -85.15M.

Is scPharmaceuticals Inc (SCPH) currently rated as Buy, Hold, or Sell?

According to analysts, scPharmaceuticals Inc (SCPH) has an overall rating of --, with a price target of 12.088.

What is the Earnings Per Share (EPS TTM) of scPharmaceuticals Inc (SCPH)?

The Earnings Per Share (EPS TTM) of scPharmaceuticals Inc (SCPH) is -1.815.
KeyAI